LYSARCLymphoma Academic Research Organisation (France)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
M2 PHARMA-December 22, 2017-Celgene, LYSARC Provide Update on Phase III 'RELEVANCE' Study of Revlimid, Rituximab Combination in Previously Untreated Patients with Follicular Lymphoma
- Lymphoma Academic Research Organisation (LYSARC) reported results from a phase III, randomised, open-label, international clinical study (RELEVANCE), US-based Celgene Corp.
SCHOLAR-1 uses pooled, patient-level data from two of the largest randomized controlled studies in NHL, the Canadian Cancer Trials Group study Ly.12 and the Lymphoma Academic Research Organization (LYSARC) Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) study, and from two observational cohorts from MD Anderson Cancer Center and the Molecular Epidemiology Resource of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence (IA/MC).